Literature DB >> 28629526

Erythropoietin Receptor Signaling and Lipid Rafts.

Kathy McGraw1, Alan List2.   

Abstract

Erythropoiesis is tightly regulated by the growth factor erythropoietin (Epo). Signal activation begins when Epo engages its cognate receptor, Epo-R, triggering receptor homodimerization, and recruitment of signaling intermediates including Jak2 that phosphorylates both the receptor cytoplasmic tail and downstream effectors including the transcription factor, STAT5. Transcription factors subsequently activate transcription of prosurvival and prodifferentiation genes responsible for red blood cell production. The fidelity of Epo-R signaling is dependent upon residence within detergent insoluble membrane lipid raft fractions. Lipid rafts are membrane microdomains that serve as signaling scaffolds composed of densely packed sphingolipids and cholesterol where receptors and intermediate signaling proteins are recruited and interact to execute stimuli. Disruption of lipid rafts is detrimental to Epo signaling, a phenomenon that may be utilized to design novel therapeutics for conditions in which Epo signaling is deficient. Here, we review the Epo signaling cascade, particularly, as it relates to localization and dependence on lipid rafts, and discuss considerations for novel therapeutic design.
© 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Erythropoietin; GTPases; Lipid rafts; Myelodysplastic syndromes; Receptor signaling

Mesh:

Substances:

Year:  2017        PMID: 28629526      PMCID: PMC7771362          DOI: 10.1016/bs.vh.2017.02.002

Source DB:  PubMed          Journal:  Vitam Horm        ISSN: 0083-6729            Impact factor:   3.421


  41 in total

1.  Lipid raft detecting in membranes of live erythrocytes.

Authors:  Ilya Mikhalyov; Andrey Samsonov
Journal:  Biochim Biophys Acta       Date:  2011-04-12

2.  Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases.

Authors:  Yibing Xu; Jianwu Li; Gregory D Ferguson; Frank Mercurio; Gody Khambatta; Lisa Morrison; Antonia Lopez-Girona; Laura G Corral; David R Webb; Brydon L Bennett; Weilin Xie
Journal:  Blood       Date:  2009-05-05       Impact factor: 22.113

3.  Erythropoietin-induced activation of STAT5 is impaired in the myelodysplastic syndrome.

Authors:  L H Hoefsloot; M P van Amelsvoort; L C Broeders; D C van der Plas; K van Lom; H Hoogerbrugge; I P Touw; B Löwenberg
Journal:  Blood       Date:  1997-03-01       Impact factor: 22.113

4.  Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin.

Authors:  L Mantovani; G Lentini; B Hentschel; P D Wickramanayake; M Loeffler; V Diehl; H Tesch
Journal:  Br J Haematol       Date:  2000-05       Impact factor: 6.998

Review 5.  Adverse events of erythropoietin in long-term and in acute/short-term treatment.

Authors:  G Singbartl
Journal:  Clin Investig       Date:  1994

6.  Cytoplasmic remodeling of erythrocyte raft lipids during infection by the human malaria parasite Plasmodium falciparum.

Authors:  Sean C Murphy; Sebastian Fernandez-Pol; Paul H Chung; S N Prasanna Murthy; Stephen B Milne; Marcela Salomao; H Alex Brown; Jon W Lomasney; Narla Mohandas; Kasturi Haldar
Journal:  Blood       Date:  2007-05-25       Impact factor: 22.113

Review 7.  Erythropoietin: physiology and pharmacology update.

Authors:  James W Fisher
Journal:  Exp Biol Med (Maywood)       Date:  2003-01

8.  Erythropoietin receptor signaling is membrane raft dependent.

Authors:  Kathy L McGraw; Gwenny M Fuhler; Joseph O Johnson; Justine A Clark; Gisela C Caceres; Lubomir Sokol; Alan F List
Journal:  PLoS One       Date:  2012-04-03       Impact factor: 3.240

Review 9.  JAK2 V617F: a single mutation in the myeloproliferative group of disorders.

Authors:  Donal McLornan; Melanie Percy; Mary Frances McMullin
Journal:  Ulster Med J       Date:  2006-05

10.  Further evidence that paroxysmal nocturnal haemoglobinuria is a disorder of defective cell membrane lipid rafts.

Authors:  Mariusz Z Ratajczak; Sylwia Borkowska; Kasia Mierzejewska; Magda Kucia; Ewa Mendek-Czajkowska; Malwina Suszynska; Vivek A Sharma; Andrzej Deptala; Wechao Song; Uwe Platzbecker; Loree Larratt; Anna Janowska-Wieczorek; Jarek Maciejewski; Janina Ratajczak
Journal:  J Cell Mol Med       Date:  2015-05-29       Impact factor: 5.310

View more
  7 in total

1.  Effects of PHD and HSP90 on erythropoietin production in yak (Bos grunniens) renal interstitial fibroblast-like cells under hypoxia.

Authors:  Yan Cui; Hui Li; Si-Jiu Yu; Seth Yaw Afedo; Xue-Feng Bai
Journal:  J Mol Histol       Date:  2022-01-27       Impact factor: 2.611

2.  Genome Wide Assessment of Genetic Variation and Population Distinctiveness of the Pig Family in South Africa.

Authors:  Nompilo Lucia Hlongwane; Khanyisile Hadebe; Pranisha Soma; Edgar Farai Dzomba; Farai Catherine Muchadeyi
Journal:  Front Genet       Date:  2020-05-07       Impact factor: 4.599

Review 3.  The Evolution of Cholesterol-Rich Membrane in Oxygen Adaption: The Respiratory System as a Model.

Authors:  Juan Pablo Zuniga-Hertz; Hemal H Patel
Journal:  Front Physiol       Date:  2019-10-29       Impact factor: 4.566

4.  Neurological recovery and antioxidant effect of erythropoietin for spinal cord injury: A systematic review and meta-analysis.

Authors:  Ya-Yun Zhang; Min Yao; Ke Zhu; Rui-Rui Xue; Jin-Hai Xu; Xue-Jun Cui; Wen Mo
Journal:  Front Neurol       Date:  2022-07-19       Impact factor: 4.086

Review 5.  Alternative Erythropoietin Receptors in the Nervous System.

Authors:  Daniela Ostrowski; Ralf Heinrich
Journal:  J Clin Med       Date:  2018-02-02       Impact factor: 4.241

6.  Suppression of NLRP3 Inflammasome by Erythropoietin via the EPOR/JAK2/STAT3 Pathway Contributes to Attenuation of Acute Lung Injury in Mice.

Authors:  Fei Cao; Xinyi Tian; Zhongwang Li; Ya Lv; Jun Han; Rong Zhuang; Bihuan Cheng; Yuqiang Gong; Binyu Ying; Shengwei Jin; Ye Gao
Journal:  Front Pharmacol       Date:  2020-03-19       Impact factor: 5.810

Review 7.  Treatment of Neonatal Hypoxic-Ischemic Encephalopathy with Erythropoietin Alone, and Erythropoietin Combined with Hypothermia: History, Current Status, and Future Research.

Authors:  Dorothy E Oorschot; Rachel J Sizemore; Ashraf R Amer
Journal:  Int J Mol Sci       Date:  2020-02-21       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.